[go: up one dir, main page]

AR005970A1 - Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo - Google Patents

Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo

Info

Publication number
AR005970A1
AR005970A1 ARP970100727A ARP970100727A AR005970A1 AR 005970 A1 AR005970 A1 AR 005970A1 AR P970100727 A ARP970100727 A AR P970100727A AR P970100727 A ARP970100727 A AR P970100727A AR 005970 A1 AR005970 A1 AR 005970A1
Authority
AR
Argentina
Prior art keywords
compounds
active agent
pharmaceutical formulations
benzotiofen
formulations containing
Prior art date
Application number
ARP970100727A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604912.7A external-priority patent/GB9604912D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR005970A1 publication Critical patent/AR005970A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se trata de compuestos de benzotiofeno de fórmula (I) útiles para el tratamiento y prevención de síndromes postmenopáusicos y carciomas de mamas.Se incluyen las formulaciones farmacéuticas que contienen dichos compuestos como agenteactivo
ARP970100727A 1996-02-22 1997-02-21 Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo AR005970A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1204496P 1996-02-22 1996-02-22
GBGB9604912.7A GB9604912D0 (en) 1996-03-08 1996-03-08 Benzothiophenes, formulations containing same, and methods

Publications (1)

Publication Number Publication Date
AR005970A1 true AR005970A1 (es) 1999-07-21

Family

ID=26308887

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970100726A AR005969A1 (es) 1996-02-22 1997-02-21 Procedimiento para preparar composiciones farmaceuticas que contienen benzotiofenos como agente activo, en unidades dosificadas o formulaciones de dosis multiple
ARP970100727A AR005970A1 (es) 1996-02-22 1997-02-21 Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970100726A AR005969A1 (es) 1996-02-22 1997-02-21 Procedimiento para preparar composiciones farmaceuticas que contienen benzotiofenos como agente activo, en unidades dosificadas o formulaciones de dosis multiple

Country Status (23)

Country Link
EP (1) EP0791591B1 (es)
JP (1) JP2000505455A (es)
KR (1) KR19990087091A (es)
CN (1) CN1211921A (es)
AR (2) AR005969A1 (es)
AT (1) ATE204869T1 (es)
AU (1) AU713204B2 (es)
BR (1) BR9707657A (es)
CA (1) CA2246721A1 (es)
CO (1) CO4761064A1 (es)
CZ (1) CZ260798A3 (es)
DE (1) DE69706338T2 (es)
DK (1) DK0791591T3 (es)
EA (1) EA000767B1 (es)
ES (1) ES2162196T3 (es)
IL (1) IL125863A (es)
NO (1) NO983802L (es)
NZ (1) NZ331461A (es)
PL (1) PL328832A1 (es)
PT (1) PT791591E (es)
TR (1) TR199801612T2 (es)
WO (1) WO1997030709A1 (es)
YU (1) YU6797A (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304138A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Benzothiophenes
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
ATE274507T1 (de) * 2000-12-05 2004-09-15 Hoffmann La Roche Benzofuran- und benzothiophen-derivative als selektive cox-2 inhibitoren
EP1782810A3 (en) * 2002-07-22 2007-05-23 Eli Lilly & Company Selective estrogen receptor modulators containing a phenylsulfonyl group
BR0312675A (pt) * 2002-07-22 2005-05-03 Lilly Co Eli Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
NZ541126A (en) * 2003-02-25 2008-07-31 Lilly Co Eli Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
EP1713770A1 (en) * 2004-01-29 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
CN111018770A (zh) * 2019-12-26 2020-04-17 北京鑫开元医药科技有限公司 一种巴多昔芬氧化物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200204A (en) * 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents

Also Published As

Publication number Publication date
EA000767B1 (ru) 2000-04-24
PL328832A1 (en) 1999-02-15
NO983802D0 (no) 1998-08-19
JP2000505455A (ja) 2000-05-09
IL125863A (en) 2000-10-31
BR9707657A (pt) 1999-07-27
IL125863A0 (en) 1999-04-11
AU713204B2 (en) 1999-11-25
TR199801612T2 (xx) 1998-11-23
EP0791591A1 (en) 1997-08-27
DK0791591T3 (da) 2001-10-08
DE69706338T2 (de) 2002-06-13
WO1997030709A1 (en) 1997-08-28
PT791591E (pt) 2001-12-28
EP0791591B1 (en) 2001-08-29
ES2162196T3 (es) 2001-12-16
DE69706338D1 (de) 2001-10-04
AR005969A1 (es) 1999-07-21
CA2246721A1 (en) 1997-08-28
CZ260798A3 (cs) 1999-05-12
CO4761064A1 (es) 1999-04-27
NZ331461A (en) 1999-05-28
KR19990087091A (ko) 1999-12-15
EA199800753A1 (ru) 1999-02-25
NO983802L (no) 1998-08-19
AU2276497A (en) 1997-09-10
CN1211921A (zh) 1999-03-24
YU6797A (sh) 1999-09-27
ATE204869T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2088388T3 (es) Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2165614T3 (es) Composiciones fluidas desodorantes/antitranspirantes.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES503650A0 (es) Procedimiento para la trimetilsililacion de compuestos organicos que llevan uno o mas atomo de hidrogeno activo.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
MX9100441A (es) Procedimiento para fabricar preparados solidos orales,que contienen ifosfamida como agente activo
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.